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Determining risk factors 
for mortality in liver 
transplant patients with 
COVID-19
We read with great interest the 
Correspondence from Bhoori and 
colleagues1 describing the effect of 
coronavirus disease 2019 (COVID-19) 
on their centre’s adult liver transplant 
population.1 Within their cohort of 
over 150 transplant recipients, the 
authors identified six patients with 
COVID-19, including three resulting 
deaths. Each of those who died was 
transplanted over 10 years previously 
and were older than 65 years, male, 
overweight, and had hypertension 
and diabetes. The authors speculated 
as to whether these characteristics 
might be major risk factors for 
mortality.
We operate two collaborating 
international registries (SECURE 
Cirrhosis covering the Americas, China, 
Japan, and South Korea; and COVID-
Hep covering the rest of the world) 
working to collate details of patients 
with chronic liver disease and post-
liver transplantation who develop 
COVID-19. As of April 22, 2020, we 
have received submissions from 
21 countries. Here, we summarise 
details of the 39 liver transplant 
recipients who developed COVID-19, 
including nine (23%) who died from 
respiratory failure (table).
By contrast with the experience 
of Bhoori and colleagues, the 
deaths in our cohort included four 
patients transplanted within the past 
2 years, with a median age younger 
than 65 years, and 44% women. 
Among the patients who died, 
four (44%) had diabetes, four (44%) 
had hypertension, and three (33%) 
were obese. Although our numbers 
were small, the frequencies of these 
comorbidities were not significantly 
different between those of fatal and 
non-fatal cases of COVID-19 (table). 
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Survived (n=30) Died (n=9) p value
Age (years) 58 (50–64) 63 (61–67) 0·102
Sex ·· ·· 0·696
Male 20 (67%) 5 (56%) ··
Female 10 (33%) 4 (44%) ··
Overweight (BMI >25 kg/m2) 19 (63%) 7 (78%) 0·695
Obese (BMI >30 kg/m2) 7 (23%) 3 (33%) 0·679
Heart disease 4 (13%) 2 (22%) 0·607
Diabetes 11 (37%) 4 (44%) 0·711
Arterial hypertension 14 (47%) 4 (44%) 1·000
Time from transplant (years) 5 (2–11) 6 (1–8) 0·580
Baseline laboratory characteristics
Serum sodium (mmol/L) 138 (137–141) 138 (136–139) 0·266
Serum total bilirubin (µmol/L) 10 (7–13) 10 (8–15) 0·570
Serum albumin (g/L) 40 (37–42) 37 (33–38) 0·025
Serum creatinine (µmol/L) 109 (80–133) 141 (111–186) 1·000
Prothrombin time (s) 12 (11–14) 12 (11–15) 0·930
Immunosuppressive drugs
Prednisone or prednisolone 10 (33%) 6 (67%) 0·123
Tacrolimus 27 (90%) 8 (89%) 1·000
Sirolimus 2 (7%) 0 (0%) 1·000
Mycophenolate mofetil 16 (53%) 4 (44%) 0·716
Data are n (%) or median (IQR). BMI=body-mass index. p values were calculated using Wilcoxon rank-sum or 
Fisher’s exact tests as appropriate.
Table: Baseline characteristics of 39 patients with previous liver transplant and laboratory-
confirmed COVID-19 submitted to the COVID-Hep and SECURE Cirrhosis registries
These conflicting findings are further 
reinforcement that greater case 
numbers are urgently required to 
accurately inform our understanding 
of individual risk.
Collating and analysing rapidly 
emerging data will be vital for 
identifying modifiable risk factors 
for severe COVID-19 among liver 
transplant recipients. For example, 
different  immunosuppression 
regimens might confer differential 
risk and changes to these medications 
might mitigate the risk of COVID-19 
complications.
Although early data suggest that 
the effects of COVID-19 on the 
liver might be modest and reflect 
infection severity among patients 
without pre-existing liver disease, 
the effects of COVID-19 on those 
with liver transplants or established 
liver disease remain unclear.2 We call 
on all those caring for patients with 
previous liver transplantation and 
other forms of chronic liver disease 
to use registries to pool details 
of COVID-19 cases and so permit 
the rapid large-scale collaborative 
analyses that are required to inform 
clinical care.
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